FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

By M. Riminucci, M. Collins, N. Fedarko, Natasha Cherman, A. Corsi, K. White, S. Waguespack, Anurag Gupta, T. Hannon, M. Econs and 2 more. Journal of Clinical Investigation, 2003

621 citations recorded by the source corpus.

Subfields: Nephrology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b2b528e773c88db8c9266f0ce8805ad657bedb9e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Q. Luo
2. L. Quarles
3. Jason R. Stubbs
4. Min Pi
5. Jianping Zhou
6. Wen Tang
7. Shiguang Liu

Citations in the corpus

• Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. (2006, background): “Increased production of FGF23 is the cause of phosphaturia and disordered vitamin D metabolism in tumor-induced osteomalacia (6,7), X-linked hypophosphatemic rickets (XLH) (7,8), and McCune-Albright syndrome (9).”